InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,521.68
(
1.57%
)
US TECH 100
18,777.60
(
2.60%
)
Dow Jones
41,016.16
(
0.67%
)
Brent Oil
80.73
(
2.75%
)
Bitcoin
66,392.71
(
0.34%
)
Post# of 252751
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120167
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 219997

Friday, 11/09/2018 5:24:21 PM

Friday, November 09, 2018 5:24:21 PM

Post# of 252751
FDA approves Keytruda monotherapy for second-line HCC:

https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-212100345.html

This is an accelerated approval based on ORR (17%) and duration of response in the single-arm KEYNOTE-224 study. Patients were either refractory to, or ineligible for, Sutent, or had Child-Pugh-A cirrhosis. Today is the PDUFA date.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up